384 results
8-K
EX-3.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
19 Apr 24
Amendments to Articles of Incorporation or Bylaws
4:06pm
in settlement or judgment and any other costs and expenses of any nature or kind incurred in connection with any proceeding.
(c) The term
8-K
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
1 Dec 23
Entry into a Material Definitive Agreement
8:25am
and nature of the market for QTORIN rapamycin and any other product candidates, including potential competition, patient and payer perceptions
8-K/A
EX-99.1
8j3s8d6xckqf nh
9 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
9:48pm
8-K
EX-99.1
bvb pfh6z6mq6b1ajg
8 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
4:08pm
8-K
exjxew6 ep7j
18 Oct 23
Other Events
9:03am
8-K
EX-10.1
mhm0jd6yto74swh7f
17 Oct 23
Entry into a Material Definitive Agreement
7:24pm
8-K
EX-99.1
dnijt ndxo
8 Aug 23
Ligand Reports Second Quarter 2023 Financial Results
4:02pm
8-K
EX-99.1
akiu2e2vjpc90 j38
4 May 23
Ligand Reports First Quarter 2023 Financial Results
4:06pm
S-3ASR
EX-1.2
1caf65
30 Sep 22
Automatic shelf registration
4:17pm
S-3ASR
EX-4.3
u7gu7 zkzd
30 Sep 22
Automatic shelf registration
4:17pm
425
EX-99.1
f9wglbf31yhe0
21 Jun 22
Business combination disclosure
8:00am
8-K
EX-99.1
ukk5r95g1s06puzr3o
21 Jun 22
Regulation FD Disclosure
6:19am